Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652983 | 1.00 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL31240185 | 0.77 | CYP17A1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL8181677 | 0.77 | CYP17A1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL31214086 | 0.74 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL25618878 | 0.73 | CYP11B1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL28305894 | 0.73 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL31214084 | 0.73 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL16815471 | 0.72 | EGFR (0.30) | — | |
| SCHEMBL2888567 | 0.70 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL29324345 | 0.70 | P2RX3 (0.34) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240245682-A1 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-109906224-B | Triazolopyridine compounds and uses thereof | 诺华股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3472161-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| CN-109906224-A | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | 诺华股份有限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-106456639-B | Prodrugs of HIV Reverse Transcriptase Inhibitors | 默沙东公司 | 2019-05-10 | — | — | CN | disclosed |
| EP-3472161-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| CN-109414415-A | The treatment of cutaneous lesions | 皮奎尔治疗公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-104822670-B | 5-phenoxy-3H-pyrimidin-4-one derivatives and their use as HIV reverse transcriptase inhibitors | 默沙东公司 | 2018-01-12 | — | — | CN | disclosed |
| WO-2017221092-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
| CN-107108644-A | Difluoromethyl aminopyridine and difluoromethyl aminopyrimidine | 皮奎尔治疗公司 | 2017-08-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, EED, BMI1 | CYP11B1 1187/4885CYP11B2 1330/4885 |
| US-20240245682-A1 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | ITGB8, ITGAV, ITGA8 | CYP11B1 4080/4885CYP11B2 4057/4885 |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | EZH2, EED, BMI1 | CYP11B1 1187/4885CYP11B2 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.